Creative Biolabs Unveils Integrated LBP Pipeline to Accelerate Multi-Strain Therapies

Creative Biolabs, a leading biotechnology CRO, has unveiled an integrated service suite designed to accelerate the development of multi-strain live biotherapeutic products (LBPs) from discovery to IND filing. The new platform addresses critical industry challenges such as consortium stability and regulatory compliance during manufacturing scale-up. Key services include designing defined microbial consortia and conducting compatibility testing, which evaluates physical and biochemical interactions between strains to ensure synergy, and mapping cross-feeding interactions within synthetic communities through advanced metabolomics. Additionally, a comprehensive preclinical CMC gap assessment audits existing data against FDA and EMA guidelines, identifying deficiencies in cell bank characterization and fermentation scale-up to provide actionable roadmaps for IND readiness. The Technical Director of Microbiome Therapeutics at Creative Biolabs emphasized that the integrated platform de-risks development by validating compatibility, mapping metabolic dependencies, and aligning manufacturing data with regulatory frameworks. Early industry feedback indicates that proactive gap assessments and rigorous evaluations have reduced pre-IND timelines and minimized clinical hold risks. This holistic approach supports biopharma developers in navigating the complex regulatory landscape and accelerating clinical translation of multi-strain therapies.